Weight management, acupuncture and more: Natural remedies that help relieve arthritis pain
(Natural News) Arthritis is a general term for a group of degenerative conditions that target the joints and the tissues that surround the joints. There are several types of arthritis including osteoarthritis, rheumatoid arthritis and psoriatic arthritis. Although each type is influenced by unique factors, arthritis is generally marked by chronic inflammation in the hands,... (Source: NaturalNews.com)
Source: NaturalNews.com - May 4, 2020 Category: Consumer Health News Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion av...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Modifiable Risk Factors for Development of Psoriatic Arthritis Modifiable Risk Factors for Development of Psoriatic Arthritis
This study examined weight reduction as well as smoking as potential modifiable risk factors for PsA.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Apremilast less costly in biologic-na ïve patients with psoriatic arthritis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2020 Category: Drugs & Pharmacology Source Type: news

Evaluating risk of cancer in patients with psoriasis, psoriatic arthritis
(JAMA Network) This observational study was a systematic review and meta-analysis that included 112 studies and examined the association between risk of cancer in patients with psoriasis or psoriatic arthritis, including the risk of specific cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news

Weight Loss and Severity of Psoriasis or Psoriatic Arthritis Weight Loss and Severity of Psoriasis or Psoriatic Arthritis
This review examined the impact of weight loss on pre-existing psoriasis or psoriatic arthritis. Might losing weight prevent the onset of psoriasis in obese individuals?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 10, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Rates of Joint Surgery Higher With Psoriatic Arthritis
MONDAY, Nov. 25, 2019 -- The five-year incidence rate of joint surgery in psoriatic arthritis (PsA) patients is twice as high as in the general population, and this rate has remained steady over time, according to a study published in the November... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 25, 2019 Category: Pharmaceuticals Source Type: news

Amgen completes acquisition of Otezla ® (apremilast)
Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (NASDAQ:CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE:BMY), which was completed on Nov. 20. (Source: World Pharma News)
Source: World Pharma News - November 21, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2019 Category: Pharmaceuticals Source Type: news

ACR: Age at Psoriasis Onset Sets Course for Psoriatic Arthritis
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 12, 2019 Category: Pharmaceuticals Source Type: news

TREMFYA ® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Findings from the DISCOVER-1 and DISCOVER-2 studies are presented, for the first time, at the 2019 American College of Rheumatology and Association of Rheumatology Professionals Annual MeetingThese are the first Phase 3 results evaluating p19-specific IL-23 inhibition in active psoriatic arthritis (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 11, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: Can you prevent psoriatic arthritis?
It is impossible to know who will develop psoriatic arthritis, though it usually affects people who already have psoriasis. Learn about whether people can prevent psoriatic arthritis here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 4, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Novartis Cosentyx ® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1]. (Source: World Pharma News)
Source: World Pharma News - November 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Medical News Today: What are the complications of psoriatic arthritis?
There are many possible complications of psoriatic arthritis, including uveitis, kidney disease, and depression. Learn about the risks and preventive steps here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 30, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Medical News Today: What to know about distal interphalangeal joint pain
Distal interphalangeal joint pain is often due to osteoarthritis or psoriatic arthritis. Learn more about the causes and their symptoms in this article. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 29, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Biologic DMARD Treatment and Bone Strength and Structure in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - October 17, 2019 Category: Orthopaedics Tags: CME Article Source Type: news

Effect of DMARDs on Bone Structure and Strength in PsA Effect of DMARDs on Bone Structure and Strength in PsA
In what ways might DMARD treatment impact bone structure and strength in patients with psoriatic arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis
The interleukin-17A inhibitor is now indicated for the treatment of adults with active ankylosing spondylitis, as well as for certain patients with plaque psoriasis and active psoriatic arthritis.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 26, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Amgen To Acquire Otezla(R) For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World Acquisition Expected to Accelerate Growth and Enhance Value for Amgen Shareholders Amgen to Host Call With Investors at 5 a.m. PT (8 a.m. ET) THOUSAND ... Biopharmaceuticals, Acquisitions Amgen, Celgene, Otezla, apremilast, psoriasis, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2019 Category: Pharmaceuticals Source Type: news

Amgen to acquire Otezla ® for $13.4 billion in cash
Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits. (Source: World Pharma News)
Source: World Pharma News - August 26, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

August 2019
Period Problems : Fibroids, Endometriosis, and Other Issues Bulging Veins : What to Do About Varicose Veins Dr. Stacey Missmer on Painful Periods in Teens More Steps for Better Health What is Psoriatic Arthritis? Urologic Diseases (Source: NIH News in Health)
Source: NIH News in Health - August 5, 2019 Category: Consumer Health News Source Type: news

Medical News Today: A guide to psoriatic arthritis medication
Medications can relieve the symptoms of psoriatic arthritis, slow disease progression, and reduce or prevent joint damage. We explore the current treatments and medication advances here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 24, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

August 2019
Period Problems : Fibroids, Endometriosis, and Other Issues Bulging Veins : What to Do About Varicose Veins Dr. Stacey Missmer on Painful Periods in Teens More Steps for Better Health What is Psoriatic Arthritis? Urologic Diseases (Source: NIH News in Health)
Source: NIH News in Health - July 24, 2019 Category: Consumer Health News Source Type: news

Long-Term Experience With Apremilast in Psoriatic Arthritis Long-Term Experience With Apremilast in Psoriatic Arthritis
A new analysis shows that apremilast may be safe and effective for longer-term treatment of psoriatic arthritis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Medical News Today: What to know about Xeljanz
This article provides an overview of its uses, how it works, and side effect warnings. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2019 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

BMS to divest Celgene drug to speed delayed deal
Bristol-Myers Squibb said it is planning to sell Otezla, Celgene's treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 24, 2019 Category: Pharmaceuticals Source Type: news

BMS to divest Celgene drugs to speed delayed deal
Bristol-Myers Squibb said it is planning to sell Otezla, Celgene's treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 24, 2019 Category: Pharmaceuticals Source Type: news

Interleukin-17 Edges TNF Inhibitor in Psoriatic Arthritis Interleukin-17 Edges TNF Inhibitor in Psoriatic Arthritis
Early outcomes for the combined end point of skin clearance and disease activity in a comparison of biologics can give physicians confidence in the IL-17 inhibitor, SPIRIT-H2H investigators say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2019 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Janssen reports top-line Phase 3 results for TREMFYA ® (guselkumab) in adults with active psoriatic arthritis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 14, 2019 Category: Pharmaceuticals Source Type: news

Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Data are part of the DISCOVER 1 and 2 program, the first Phase 3 studies to evaluate a selective IL-23 p19 inhibitor in the treatment of psoriatic arthritis HORSHAM, Pa., June 14, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceut... Biopharmaceuticals Janssen Pharmaceutical, Johnson & Johnson, TREMFYA, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2019 Category: Pharmaceuticals Source Type: news

Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
INDIANAPOLIS, June 14, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriati... Biopharmaceuticals Eli Lilly, psoriatic arthritis, Taltz, ixekizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2019 Category: Pharmaceuticals Source Type: news

No link between cancer and tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest that overall cancer risk is not linked to tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2019 Category: Cancer & Oncology Source Type: news

Being overweight linked to significantly higher disease severity in psoriatic arthritis
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate significant correlation between body mass index (BMI) and disease severity in psoriatic arthritis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news

Imaging tests help reveal heart risks in patients with psoriatic disease
(Wiley) Patients with psoriasis and psoriatic arthritis -- collectively termed psoriatic disease -- face increased heart risks. A new study published in Arthritis& Rheumatology indicates that ultrasound imaging of the carotid arteries can reveal the extent to which patients' arteries are clogged and also indicate their risk of experiencing future cardiovascular events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 5, 2019 Category: International Medicine & Public Health Source Type: news

Medical News Today: Can acupuncture help with psoriasis?
Many researchers have looked at the effects of acupuncture on psoriasis and psoriatic arthritis. In this article, we look at how acupuncture can help, what the research says, and how to get acupuncture for psoriasis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 4, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news

Ask Is Psoriatic Arthritis Considered a Disability
Is Psoriatic Arthritis Considered a Disability? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 6, 2019 Category: General Medicine Source Type: news

FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases
Etanercept-ykro (Eticovo) is approved across all eligible indications for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.FDA Approvals (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2019 Category: Rheumatology Tags: Rheumatology News Alert Source Type: news

Medical News Today: What to know about tumor necrosis factor
Tumor necrosis factor is a protein involved in inflammation. Excess tumor necrosis factor (TNF) in the blood has a role in inflammatory conditions, such as forms of arthritis and irritable bowel disease. In this article, we look at TNF, its links with medical conditions, and how to reduce TNF levels. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 1, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
This marks the first regulatory approval globally for SKYRIZI™ (risankizumab) SKYRIZI is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit[1] NORTH CHICAGO, Ill., March 26, 20... Biopharmaceuticals, Regulatory AbbVie, SKYRIZI, risankizumab, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 26, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: What to know about psoriatic arthritis mutilans
Arthritis mutilans most often occurs in people with psoriatic arthritis, though it is very rare today because of advances in medications for psoriatic arthritis. Arthritis mutilans can cause severe hand or foot abnormalities. In this article, we look at the symptoms, causes, and treatment of this condition. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 20, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Medical News Today: What to know about psoriatic arthritis jaw pain
Psoriatic arthritis (PsA) can affect any joint in the body, including the jaw. This can cause jaw pain, teeth grinding, and other dental problems. In this article, we explore the symptoms and complications, and we discuss ways to relieve PsA jaw pain at home and with medical treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 20, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Medical News Today: How can psoriatic arthritis affect the feet?
Psoriatic arthritis can have many effects on the body. In this article, we look at how the condition can affect the feet, including symptoms, risk factors, treatments, and home remedies. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 18, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Psoriatic Arthritis and Road to Bone Damage
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - March 17, 2019 Category: Orthopaedics Tags: CME Article Source Type: news

Medical News Today: What to know about psoriatic spondylitis
Psoriatic spondylitis is a form of arthritis that affects the spine. It can develop anywhere between the lower back and the neck. In this article, we look at the symptoms, causes, and treatment of psoriatic spondylitis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Medical News Today: Stelara vs. Humira: What's the difference?
Stelara and Humira are two biologics that help treat immune conditions, such as psoriatic arthritis and Crohn ’s disease. In this article, we look at the similarities and differences in their effects, benefits, and risks. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2019 Category: Consumer Health News Tags: Rheumatology Source Type: news

Medical News Today: What is the link between psoriatic arthritis and depression?
Psoriatic arthritis (PsA) can contribute to some mental health conditions, including depression. In this article, we look at the link between PsA and depression, as well as treatments and coping strategies. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 13, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Medical News Today: Top 10 cold weather tips for psoriatic arthritis
In many people with psoriatic arthritis, cold weather can cause symptoms to flare. In this article, we discuss ways to manage psoriatic arthritis in cold weather, both in the short and long term. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 11, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Medical News Today: Psoriatic arthritis and weight gain: What to know
People who are overweight are more likely to get psoriatic arthritis, and this condition can make it difficult for people to exercise. In this article, we look at the link between psoriatic arthritis and weight gain, including safe ways to lose weight with this condition. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 11, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Psoriatic Arthritis: What Role for Methotrexate?
(MedPage Today) -- Trial data indicates it helps with some symptoms, for others not so much (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 18, 2019 Category: Dermatology Source Type: news